AstraZeneca's (AZN) sBLA for Enhertu Gets FDA's Priority Tag
AstraZeneca(US:AZN) Zacks Investment Research·2024-01-30 21:46AstraZeneca新闻 - FDA对AstraZeneca的Enhertu进行了优先审查，扩大其使用范围[1] - Enhertu是由AstraZeneca和大日本制药共同开发的HER2定向抗体药物复合物[2] - FDA正在根据RTOR计划和Project Orbis审查sBLA[3]